Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 2, 2016

Study Completion Date

May 2, 2016

Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
DRUG

dimethyl fumarate

Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.

BIOLOGICAL

tetanus diphtheria toxoids vaccine

Administered as described in the treatment arm

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

Administered as described in the treatment arm

BIOLOGICAL

meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)

Administered as described in the treatment arm

DRUG

non-pegylated interferon

Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.

Trial Locations (14)

10016

Research Site, New York

28203

Research Site, Charlotte

33312

Research Site, Fort Lauderdale

34243

Research Site, Sarasota

40513

Research Site, Lexington

44195

Research Site, Cleveland

44320

Research Site, Akron

45417

Research Site, Dayton

46202

Research Site, Indianapolis

78258

Research Site, San Antonio

78761

Research Site, Round Rock

80233

Research Site, Thornton

85234

Research Site, Gilbert

04210

Research Site, Auburn

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY